Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients
The data on the coronavirus disease (COVID-19) in solid-organ transplant recipients (SOTRs) in Croatia is unknown. The aim of this study was to analyze the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Croatian SOTRs.From 7 September to 27 November 2020 (beginning...
| Permalink: | http://skupni.nsk.hr/Record/nsk.NSK01001163304/Details |
|---|---|
| Matična publikacija: |
Biochemia medica (Online) 31 (2021), 3 ; str. 487-493 |
| Glavni autori: | Mrzljak, Anna (Author), Jureković, Željka, Pavičić-Šarić, Jadranka, Stevanović, Vladimir, Tabain, Irena, Hruškar, Željka, Mikulić, Danko, Barbić, Ljubo, Vilibić-Čavlek, Tatjana |
| Vrsta građe: | e-članak |
| Jezik: | eng |
| Online pristup: |
https://doi.org/10.11613/BM.2021.030901 Elektronička verzija članka Elektronička verzija članka Elektronička verzija članka |
| LEADER | 03711naa a22004334i 4500 | ||
|---|---|---|---|
| 001 | NSK01001163304 | ||
| 003 | HR-ZaNSK | ||
| 005 | 20230213141435.0 | ||
| 006 | m d | ||
| 007 | cr|||||||||||| | ||
| 008 | 230213s2021 ci |o |0|| ||eng | ||
| 024 | 7 | |2 doi |a 10.11613/BM.2021.030901 | |
| 035 | |a (HR-ZaNSK)001163304 | ||
| 040 | |a HR-ZaNSK |b hrv |c HR-ZaNSK |e ppiak | ||
| 041 | 0 | |a eng | |
| 042 | |a croatica | ||
| 044 | |a ci |c hr | ||
| 080 | 1 | |2 2011 | |
| 100 | 1 | |a Mrzljak, Anna |4 aut |9 HR-ZaNSK | |
| 245 | 1 | 0 | |a Seroprevalence of SARS-CoV-2 in Croatian solid-organ transplant recipients |h [Elektronička građa] |c Anna Mrzljak, Željka Jureković, Jadranka Pavičić-Šarić, Vladimir Stevanović, Irena Tabain, Željka Hruškar, Danko Mikulić, Ljubo Barbić, Tatjana Vilibić-Čavlek. |
| 300 | |b Ilustr. | ||
| 504 | |a Bibliografija: | ||
| 504 | |a Summary. | ||
| 520 | |a The data on the coronavirus disease (COVID-19) in solid-organ transplant recipients (SOTRs) in Croatia is unknown. The aim of this study was to analyze the seroprevalence of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) in Croatian SOTRs.From 7 September to 27 November 2020 (beginning of the second COVID-19 pandemic wave), a cross-sectional screening for COVID-19 was performed in the adult outpatient liver (LTRs; N = 280) and kidney transplant recipients (KTRs; N = 232). Serum samples were initially tested for SARS-CoV-2 IgG antibodies using a commercial enzyme-linked immunosorbent assay (ELISA; Vircell Microbiologists, Granada, Spain). All positive samples were confirmed using a virus neutralization test (VNT). Data on risk exposure and COVID-19 related symptoms were collected using a questionnaire.The transplanted cohort"s seroprevalence detected by ELISA and VNT was 20.1% and 3.1%, respectively. Neutralizing (NT) antibodies developed in 15.6% of anti-SARS-CoV-2 ELISA IgG positive SOTRs. The difference in seropositivity rates between LTRs and KTRs was not statistically significant (ELISA 21.1% vs. 19.0%, P = 0.554; VNT 3.6% vs. 2.6%, P = 0.082). Overall VNT positivity rates were higher in patients who reported participation in large community events (5.9% vs. 1.0%; P = 0.027) as well as in patients who reported COVID-19 related symptoms in the past six months. In addition, symptomatic VNT positive patients showed significantly higher (P = 0.031) NT antibody titers (median 128, interquartile range (IQR) = 32-128) compared to asymptomatic patients (median 16, IQR = 16-48).This study showed that 15.6% of anti-SARS-CoV-2 ELISA positive Croatian SOTRs developed NT antibodies indicating protective immunity. Further studies are needed to determine the dynamic of NT antibodies and COVID-19 immunity duration in immunocompromised populations such as LTRs and KTRs. | ||
| 700 | 1 | |a Jureković, Željka |4 aut |9 HR-ZaNSK | |
| 700 | 1 | |a Pavičić-Šarić, Jadranka |4 aut |9 HR-ZaNSK | |
| 700 | 1 | |a Stevanović, Vladimir |4 aut |9 HR-ZaNSK | |
| 700 | 1 | |a Tabain, Irena |4 aut |9 HR-ZaNSK | |
| 700 | 1 | |a Hruškar, Željka |4 aut |9 HR-ZaNSK | |
| 700 | 1 | |a Mikulić, Danko |4 aut |9 HR-ZaNSK | |
| 700 | 1 | |a Barbić, Ljubo |4 aut |9 HR-ZaNSK | |
| 700 | 1 | |a Vilibić-Čavlek, Tatjana |4 aut |9 HR-ZaNSK | |
| 773 | 0 | |t Biochemia medica (Online) |x 1846-7482 |g 31 (2021), 3 ; str. 487-493 |w nsk.(HR-ZaNSK)000655372 | |
| 981 | |b Be2021 | ||
| 856 | 4 | 0 | |u https://doi.org/10.11613/BM.2021.030901 |
| 856 | 4 | 0 | |u https://www.biochemia-medica.com/en/journal/31/3/10.11613/BM.2021.030901 |y Elektronička verzija članka |
| 856 | 4 | 0 | |u https://www.biochemia-medica.com/en/journal/31/3/10.11613/BM.2021.030901/fullArticle |y Elektronička verzija članka |
| 856 | 4 | 1 | |y Digitalna.nsk.hr |
| 856 | 4 | 0 | |u https://hrcak.srce.hr/264032 |y Elektronička verzija članka |